Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Stem cells: hype and hope].

J J W M Janssen1, P C Huijgens

  • 1VU Medisch Centrum, Afd. Hematologie, De Boelelaan 1117, 1081 HV Amsterdam. jjwm.janssen@vumc.nl

Nederlands Tijdschrift Voor Geneeskunde
|August 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.

Cancer chemotherapy and pharmacology·2026
Same author

Benefits and Limitations of Real-World Patient-Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers.

Cancer medicine·2025
Same author

Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

European journal of haematology·2025
Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024
Same author

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Leukemia·2022
Same author

Indwelling time of peripherally inserted central catheters and incidence of bloodstream infections in haematology patients: a cohort study.

Antimicrobial resistance and infection control·2022
Same journal

[Insulin intoxications caused by falsified semaglutide].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Professional skepticism in medical research].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Somatic stem cells show promise for treating heart conditions, but clinical trials have yielded disappointing results. Further research is crucial to understand their therapeutic potential in myocardial infarction and heart failure.

Area of Science:

  • Regenerative Medicine
  • Stem Cell Biology
  • Cardiovascular Research

Background:

  • Embryonic stem cells face ethical and legal limitations for tissue regeneration.
  • Somatic stem cells, like haematopoietic stem cells from bone marrow, are being explored for therapeutic applications.
  • Preclinical studies show potential for bone marrow-derived cells in experimental myocardial infarction models.

Discussion:

  • Bone marrow contains both haematopoietic and potentially other non-haematopoietic stem cells.
  • The plasticity of haematopoietic stem cells may be attributed to these other stem cell populations.
  • Clinical trial outcomes for myocardial infarction and heart failure using these cells have been disappointing.

Key Insights:

  • Somatic stem cells offer an alternative to embryonic stem cells in regenerative medicine.

Related Experiment Videos

  • Bone marrow stem cell therapy shows promise in preclinical models but faces clinical translation challenges.
  • The exact mechanisms and cell types responsible for therapeutic effects require further elucidation.

    • Outlook:

    • Further investigation is needed to optimize stem cell therapies for cardiovascular diseases.
    • Understanding the role of different bone marrow stem cell populations is critical.
    • Bridging the gap between preclinical promise and clinical efficacy remains a key challenge.